• Profile
Close

Nivolumab plus ipilimumab in patients with advanced melanoma: Updated survival, response, and safety data in a phase I dose-escalation study

Journal of Clinical Oncology Feb 14, 2018

Callahan MK, et al. - In a phase I dose-escalation study, concurrent therapy with nivolumab (NIVO) and ipilimumab (IPI) showed clinical activity in patients with previously treated or untreated advanced melanoma. Herein, long-term follow-up data from study CA209-004 demonstrated a 3-year overall survival rate of 63% in patients with advanced melanoma treated with NIVO plus IPI combination therapy; this represented the highest observed rate for this patient population. Additional evidence for the durable clinical activity of immune checkpoint inhibitors in the treatment of advanced melanoma was demonstrated.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay